Overview

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.

Status:
Completed

Trial end date:
2023-02-13

Target enrollment:

Participant gender:

Summary

The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose administration under fed conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Galenicum Health

Treatments:

Metformin
Sitagliptin Phosphate